Breaking News Instant updates and real-time market news.

GILD

Gilead

$74.87

0.33 (0.44%)

04:55
11/30/16
11/30
04:55
11/30/16
04:55

Gilead management to meet with Leerink

Meeting to be held in New York on November 30 hosted by Leerink.

  • 30

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

GILD Gilead
$74.87

0.33 (0.44%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $89
LEER
Market Perform
Gilead myelofibrosis data miss may open path for M&A, says Leerink
Leerink analyst Geoffrey Porges notes that Gilead (GILD) released disappointing Phase III data for its JAK 1/2 inhibitor momelotinib in myelofibrosis. The company indicated that they plan to discuss these results with regulatory authorities to determine the next steps, but it seems likely that momelotinib will be written off, he adds. However, Porges believes that this disappointment restores Incyte (INCY) to the list of feasible candidates for acquisition by Gilead, since it would no longer face the obligation to divest one of the overlapping JAK programs. He reiterates a Market Perform rating and $89 price target on Gilead's shares.
11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

14:16
12/09/16
12/09
14:16
12/09/16
14:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:16
12/09/16
12/09
14:16
12/09/16
14:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavy for this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$12.16

-0.17 (-1.38%)

14:12
12/09/16
12/09
14:12
12/09/16
14:12
Conference/Events
Pure Storage participates in a conference call with Stifel »

Stifel's Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 12

    Jan

  • 13

    Jan

  • 09

    Dec

IX

ORIX Corp

$82.04

0.99 (1.22%)

14:10
12/09/16
12/09
14:10
12/09/16
14:10
Upgrade
ORIX Corp rating change  »

ORIX Corp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$15.43

0.585 (3.94%)

14:10
12/09/16
12/09
14:10
12/09/16
14:10
Options
Transocean short-term puts active as shares see strength »

Transocean short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NMR

Nomura

$6.70

0.22 (3.40%)

14:08
12/09/16
12/09
14:08
12/09/16
14:08
Upgrade
Nomura rating change  »

Nomura upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$57.13

-0.06 (-0.10%)

14:06
12/09/16
12/09
14:06
12/09/16
14:06
Downgrade
MetLife rating change  »

MetLife downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

14:05
12/09/16
12/09
14:05
12/09/16
14:05
General news
Treasury Action: next week's auctions could be difficult »

Treasury Action: next…

QQQ

NASDAQ 100 Index Tracking Stock

$118.57

0.21 (0.18%)

14:00
12/09/16
12/09
14:00
12/09/16
14:00
Options
Bullish yearend play in the PowerShares QQQ ETF »

Bullish yearend play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
12/09/16
12/09
13:50
12/09/16
13:50
General news
Action Economics Survey results: equities continue to charge ahead »

Action Economics Survey…

CFX

Colfax

$39.04

-0.245 (-0.62%)

13:49
12/09/16
12/09
13:49
12/09/16
13:49
Conference/Events
Colfax to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

13:45
12/09/16
12/09
13:45
12/09/16
13:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY moved…

NRE

Northstar Realty Europe Corp.

$12.13

0.36 (3.06%)

, NSAM

NorthStar Asset Management

$15.09

0.09 (0.60%)

13:44
12/09/16
12/09
13:44
12/09/16
13:44
Hot Stocks
Bow Street confirms $13 per share offer for Northstar Realty Europe Corp. »

Bow Street, which holds a…

NRE

Northstar Realty Europe Corp.

$12.13

0.36 (3.06%)

NSAM

NorthStar Asset Management

$15.09

0.09 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

CALA

Calithera Biosciences

$3.20

-0.05 (-1.54%)

13:44
12/09/16
12/09
13:44
12/09/16
13:44
Conference/Events
Calithera Biosciences to hold a conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BAC

Bank of America

$23.03

0.075 (0.33%)

13:40
12/09/16
12/09
13:40
12/09/16
13:40
Options
Eight year highs and flat skew draw ratio call spreader in Bank of America »

Eight year highs and flat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jan

VIA

Viacom

$42.60

0.45 (1.07%)

, VIAB

Viacom

$38.80

0.79 (2.08%)

13:37
12/09/16
12/09
13:37
12/09/16
13:37
Hot Stocks
Box Office Battle: 'Office Christmas Party' looks to topple 'Moana' »

Opening this weekend, and…

VIA

Viacom

$42.60

0.45 (1.07%)

VIAB

Viacom

$38.80

0.79 (2.08%)

CMCSK

Comcast

CMCSA

Comcast

$69.23

-0.1 (-0.14%)

SNE

Sony

$29.40

0.24 (0.82%)

FOXA

21st Century Fox

$28.64

0.53 (1.89%)

FOX

21st Century Fox

$28.48

0.53 (1.90%)

DIS

Disney

$103.84

0.46 (0.44%)

TWX

Time Warner

$94.89

0.34 (0.36%)

LGF

Lionsgate

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VHC

VirnetX

$2.95

-0.35 (-10.61%)

, AAPL

Apple

$112.12

1.09 (0.98%)

13:32
12/09/16
12/09
13:32
12/09/16
13:32
Hot Stocks
VirnetX says U.S. Federal Circuit Appeals Court issued three appeal decisions »

VirnetX announced that on…

VHC

VirnetX

$2.95

-0.35 (-10.61%)

AAPL

Apple

$112.12

1.09 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

AFL

Aflac

$68.79

-0.83 (-1.19%)

13:25
12/09/16
12/09
13:25
12/09/16
13:25
Options
AFLAC call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
12/09/16
12/09
13:25
12/09/16
13:25
General news
Energy Action: Weekly Baker-Hughes rig count »

Energy Action: Weekly…

TTI

TETRA

$4.61

-0.4 (-7.98%)

13:20
12/09/16
12/09
13:20
12/09/16
13:20
Downgrade
TETRA rating change  »

TETRA downgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

$NYE

NYSE Market Internals

13:16
12/09/16
12/09
13:16
12/09/16
13:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:16
12/09/16
12/09
13:16
12/09/16
13:16
Technical Analysis
NASDAQ market internals summary »

Volume is extremely heavy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$225.83

0.68 (0.30%)

, XLF

Financial Select Sector

$23.64

-0.06 (-0.25%)

13:13
12/09/16
12/09
13:13
12/09/16
13:13
Technical Analysis
On The Fly: ETF fund flow highlights »

The week saw very large…

SPY

SPDR S&P 500 ETF Trust

$225.83

0.68 (0.30%)

XLF

Financial Select Sector

$23.64

-0.06 (-0.25%)

XLP

Consumer Staples Sector SPDR

$51.86

0.56 (1.09%)

XLI

Industrial Select Sector SPDR

$63.87

0.18 (0.28%)

VOO

Vanguard S&P 500 ETF

$207.39

0.65 (0.31%)

JNK

SPDR Barclays High Yield Bond

$36.47

0.0085 (0.02%)

IEMG

iShares Core MSCI Emerging Markets

$43.94

-0.165 (-0.37%)

QQQ

NASDAQ 100 Index Tracking Stock

$118.57

0.21 (0.18%)

USO

United States Oil Fund

$11.42

0.11 (0.97%)

XOP

SPDR Oil Exploration and Production Fund

$43.19

-0.16 (-0.37%)

UWTI

VelocityShares 3x Long Crude Oil ETN

IBB

iShares Nasdaq Biotechnology Index

$268.52

2.24 (0.84%)

GLD

SPDR Gold Trust

$110.63

-0.94 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTI

TETRA

$4.61

-0.4 (-7.98%)

13:12
12/09/16
12/09
13:12
12/09/16
13:12
Downgrade
TETRA rating change  »

TETRA downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

IRM

Iron Mountain

$34.71

-0.28 (-0.80%)

13:11
12/09/16
12/09
13:11
12/09/16
13:11
Hot Stocks
Iron Mountain receives approval to sell C21 to Oasis Group »

Iron Mountain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.